STZ eyetrial Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2010
NCT01092533
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

STZ eyetrial

Active Ingredients

Drugs in Phase 3 Trials (2)

mycophenolate (CellCept) (1 trial)

prednisone (meticorten) (1 trial)

Drugs in Phase 2 Trials (3)

raav2.rep1 (1 trial)

raav.hcnga3 (1 trial)

raav.hpde6a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroideremia (Phase 2)

Color Vision Defects (Phase 2)

Pars Planitis (Phase 3)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Uveitis (Phase 3)

Uveitis, Intermediate (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5